Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Bio-Rad Laboratories (BIO) one of those stocks right now? A quick glance at the ...
Bio-Rad is back on the table as an attractive value proposition once again. The firm is well-positioned to unlock tremendous value for shareholders looking ahead, in my estimation. Profitability is a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Most of Kelderman's pay was in ...
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the ...
Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.90, which missed the Zacks Consensus Estimate of $2.93 by 1.0%. The bottom line decreased 6.4% from ...
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback